Topic Highlight
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2015; 21(42): 12083-12090
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12083
Management of hepatitis B virus infection after liver transplantation
Miguel Jiménez-Pérez, Rocío González-Grande, José Mostazo Torres, Carolina González Arjona, Francisco Javier Rando-Muñoz
Miguel Jiménez-Pérez, Rocío González-Grande, José Mostazo Torres, Carolina González Arjona, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo Hospital Regional Universitario, 29010 Malaga, Spain
Francisco Javier Rando-Muñoz, Department of Abdominals Diseases, Hospital Nij Smellinghe Ziekenhuis, 9202 NN Drachten, The Netherlands
Author contributions: Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C and Rando-Muñoz FJ contributed equally to this work.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Miguel Jiménez-Pérez, MD, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo Hospital Regional Universitario, Avenida Carlos Haya, 29010 Malaga, Spain.
Telephone: + 34-6-1095935 Fax: + 34-95-1291941
Received: April 18, 2015
Peer-review started: April 20, 2015
First decision: June 23, 2015
Revised: July 4, 2015
Accepted: September 14, 2015
Article in press: September 14, 2015
Published online: November 14, 2015

Chronic hepatitis B virus (HBV) infection is responsible for up to 30% of cases of liver cirrhosis and up to 53% of cases of hepatocellular carcinoma. Liver transplantation (LT) is the best therapeutic option for patients with end-stage liver failure caused by HBV. The success of transplantation, though, depends on receiving prophylactic treatment against post-transplant viral reactivation. In the absence of prophylaxis, liver transplantation due to chronic hepatitis B (CHB) is associated with high rates of viral recurrence and poor survival. The introduction of treatment with hepatitis B immunoglobulins (HBIG) during the 1990s and later the incorporation of oral antiviral drugs have improved the prognosis of these patients. Thus, LT for CHB is now a universally accepted option, with an estimated 5 years survival of around 85% vs the 45% survival seen prior to the introduction of HBIG. The combination of lamivudine plus HBIG has for many years been the most widely used prophylactic regimen. However, with the appearance of new more potent oral antiviral agents associated with less resistance (e.g., entecavir and tenofovir) for the treatment of CHB, new prophylactic strategies are being designed, either in combination with HBIG or alone as a monotherapy. These advances have allowed for more personalized prophylaxis based on the individual risk profile of a given patient. In addition, the small pool of donors has required the use of anti-HBc-positive donors (with the resulting possibility of transmitting HBV from these organs), which has been made possible by suitable prophylactic regimens.

Keywords: Hepatitis B virus, Liver transplantation, Recurrence, Prophylaxis, Hepatitis B immunoglobulin

Core tip: The current success of liver transplantation in patients with chronic hepatitis B (CHB)-related cirrhosis is mainly due to the use of prophylaxis with hepatitis B immunoglobulins (HBIG) and oral antivirals against post-liver transplant recurrence of CHB. The combination of low-dose HBIG plus antivirals forms the current standard prophylaxis. The use of newer antivirals (entecavir and tenofovir), coupled with better understanding of the predisposing factors for recurrence of CHB, has led to new perspectives for prophylaxis regimens, aimed at withdrawal of HBIG or the use of HBIG-free regimens, oriented toward a strategy of individualized prophylaxis.